Abstract:The coronavirus family has many pathogens that cause severe human diseases, including SARS, MERS and COVID-19.Starting from the SARS outbreak in 2003, our group has been dedicated to understanding coronavirus Replication-Transcription Complexes (RTCs).During the early part of the COVID-19 outbreak, we rapidly initiated a structural study of SARS-CoV-2 RTCs, aiming to dissect the key mechanisms for SARS-CoV-2 in human cells and provide structural information to discover potent antivirals.With great efforts from our laboratory and outside collaborations, we successfully determined the structure of the central RTC (C-RTC) composed by nsp12 (RNAdependent RNA polymerase, RdRp) with cofactors nsp7 and nsp8 1 , providing the first picture to visualize this key antiviral target.We also elucidated the mechanism of C-RTC catalysis and how remdesivir (RDV) inhibits the synthesis of RNA.This was achieved by determining the structure of C-RTC in complex with the template-product duplex RNA and the active form of RDV 2 .Subsequently, we presented the structure of the elongation RTC (E-RTC), showing how nsp13 (helicase) unwinds the highly-ordered structure in genome to yield the functional template for RNA synthesis in C-RTC 3 .After that, we discovered a key intermediate state of RTC leading towards mRNA capping [Cap(-1)'-RTC], demonstrating the nsp12 NiRAN is indeed the key enzyme to catalyze the second capping action and how it presents nsp9 as an "adaptor" for the further recruitment of capping enzymes into RTC 4 .In a following study, we assembled Cap(0)-RTC by Cap(-1)'-RTC and nsp10/nsp14, showing how the co-transcriptional capping and an in trans backtracking mechanism for proofreading concert in one RTC 5 .In our most recent work, we discovered a previously unknown protein modification -RNAylation on nsp9, and demonstrated nsp12 NiRAN utilizes the RNAylated nsp9 and GTP as substrates to synthesize the GpppA cap core, reasoning a novel RNA capping pathway 6 .We also showed that the nucleotide analogue inhibitors (NAIs) can be linked to nsp9 by NiRAN and thus block the occurrence of RNAylation and GpppA formation, furthering the understanding of the mechanism of action of NAIs.An 'induce-and-lock' mechanism is proposed to design new inhibitors against SARS-CoV-2 RNA capping.These works not only provides a basis to understand SARS-CoV-2 proliferates in the host cells through a structural biology lens, but also sheds new light for antiviral development against rapidly emerging SARS-CoV-2 variants.1

2′-O methylation of RNA cap in SARS-CoV-2 captured by serial crystallography

Structural basis of RNA cap modification by SARS-CoV-2

Reconstitution of RNA cap methylation reveals different features of SARS‐CoV‐2 and SARS‐CoV methyltransferases

Structural and functional insights into the 2'-O-methyltransferase of SARS-CoV-2

Despite the odds: formation of the SARS-CoV-2 methylation complex

Structural Basis for Inhibition of the SARS-CoV-2 nsp16 by Substrate-Based Dual Site Inhibitors

A Story of SARS-CoV-2 RNA Capping

A metal ion orients SARS-CoV-2 mRNA to ensure accurate 2'-O methylation of its first nucleotide

A metal ion orients mRNA to ensure accurate 2'- O ribosyl methylation of the first nucleotide of the SARS-CoV-2 genome

Crystal structure of SARS‐CoV‐2 nsp10–nsp16 in complex with small molecule inhibitors, SS148 and WZ16

A Mechanism for SARS-CoV-2 RNA Capping and Its Inhibition by Nucleotide Analog Inhibitors.

N -Arylsulfonamide-based adenosine analogues to target RNA cap N 7-methyltransferase nsp14 of SARS-CoV-2

SARS-CoV-2 methyltransferase nsp10-16 in complex with natural and drug-like purine analogs for guiding structure-based drug discovery

The SARS-CoV-2 RNA polymerase is a viral RNA capping enzyme

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

5'-cap RNA/SAM mimetic conjugates as bisubstrate inhibitors of viral RNA cap 2'-O-methyltransferases

Structures of SARS-CoV-2 N7-methyltransferase with DOT1L and PRMT7 inhibitors provide a platform for new antivirals

Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2’-O-Methylation of Viral RNA

Coupling of N7-methyltransferase and 3′-5′ exoribonuclease with SARS-CoV-2 polymerase reveals mechanisms for capping and proofreading

N7-Methylation of the Coronavirus RNA Cap Is Required for Maximal Virulence by Preventing Innate Immune Recognition

Structural insights into the RNA binding inhibitors of the C-terminal domain of the SARS-CoV-2 nucleocapsid